Incannex Healthcare Limited is an Australian company that specializes in the research, development, and sale of medicinal cannabinoid products. The company offers pharmaceutical grade cannabinoid products under the brand name Incannex. Its product portfolio includes IHL-42X, IHL-216A, and IHL-675A, which are designed to address various medical conditions, including obstructive sleep apnea, traumatic brain injury, inflammatory lung conditions, and rheumatoid arthritis. Incannex Healthcare Limited has partnerships with The Alfred Hospital, Novotech, and Monash Trauma Group at the Department of Neuroscience, Monash University. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in 2020. The company is based in Sydney, Australia.